Abstract 376P
Background
This study aimed to explore the beneficial of intensive nutrition intervention with intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy in the treatment of patients with locally advanced nasopharyngeal carcinoma.
Methods
174 locally advanced nasopharyngeal carcinoma patients (LANPC) receiving radical radiotherapy and concurrent cisplatin-based chemotherapy were enrolled from December, 2000 to December, 2016. Patients were divided into two groups as NI group(which received intensive, individualized nutrition education counseling and oral supplements if required), and UC group (general advice and nutrition booklet, without nutrition education). Propensity score matching was performed to balance the baseline differences between the two groups.
Results
Following one-to-one propensity score matching, survival outcomes for the matched data set indicated that the NI group achieved higher overall survival and failure-free survival (P<0.05) compared with UC. Subgroup analysis revealed that NI was associated with significantly improved OS (Hazard ratio [HR] =1.577, 95% Confidence interval [CI] = 1.055–2.357, P < 0.05) and FFS (HR = 1.53, 95% CI = 1.022–2.29, P<0.05). Additionally, the differences of the main adverse reactions after treatment between the two group were not statistically significant (P>0.05).
Conclusions
Early and intensive NI promoted beneficial outcomes in ameliorating the prognosis in loco-regionally advanced NPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract